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So far, we have not performed genetic testing on
moderate cancer risk, such as CHEK2 testing for breast
cancer. We feel that this would lead to a large number
of the population being positive and that it is unlikely
that all carriers would be offered surveillance.
Furthermore, the economic burden from surveillance
for moderate risk may not be acceptable in a situation
where patients who already have cancer would not
always be able to get the most expensive and most
effective treatments available.
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It is an interesting pilot study that requires replication
on a larger scale.
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This is an important step towards defining genetic risk
factors of breast cancer. As a medical oncologist I expect
that downstream functions of such common genetic
variants will be potential targets for new drugs [1]. Old
drugs could also become new drugs [2]. Pharmacoge-
netics, the hereditary basis for inter-individual differences
in drug effect, will predict patients at risk for extreme
toxicity and altered efficacy of chemotherapy [3, 4].
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It is practically impossible to find a paper in which
the authors raise the basic issue – why there is such 
a high frequency of hereditary forms of cancer in the
human population. I highly appreciate your approach
and courage to go into this basic problem. I think that
your hypothesis may bring a new impulse for the
solution of this crucial question.
I have a feeling that at the present time human
genetics, after a very dramatic period of approximately
20 years, is entering a period of recession. The reason
is that we are not able to answer the aforementioned
question. 
Why do so many mutations in a very short part of
human DNA result in various types of cancer diseases?
This is mainly the case of the APC gene in the part of
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the MCR where there are concentrated about 70% of
all APC germ-line mutations. The answer that this part
of the DNA is special and is predisposed to mutation
is not correct. We need to try to find another
explanation. I am trying to do so.
I think that you are absolutely right that there
should be something common in predisposition to
all malignancies. Is this genetic polymorphisms?
Probably yes.
Like many researchers who are interested in human
genetics, I have a hypothesis as well. This idea has
developed over many years and I suppose that it may
open new perspectives into human genetics. At present
I am working experimentally to confirm it. My idea is
rather different from yours.
So, there are at the moment two hypotheses!!!
Interesting!!!
And both are from Eastern Europe!!! It is funny that
new impulses are coming from this, still underrated
part of Europe.
Maybe this is the future.
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